Across TCGA pan-cancer cohorts, ZNF706 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ZNF706 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ZNF706 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF706 expression acts as an unfavorable survival marker.
OV are the cancer types where ZNF706 Mutation most reproducibly stratifies survival.